News Mundipharma to market Herceptin biosimilar in key EU markets Mundipharma's third biosimilar tie-up with Celltrion
News Its Herceptin biosimilar nearing launch, Celltrion begins wo... South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda.
News Pfizer's rituximab biosimilar gets late-stage trial boost Phase 3 success sets up showdown with Roche, Sandoz, and Celltrion
News Roche's Herceptin facing further biosimilar threats in US Breast cancer blockbuster facing potential trio of US competitors.
News Celltrion's rituximab biosimilar could have four names in EU Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
